Hangzhou Tigermed Consulting Co., Ltd 300347.SZ Stock
Hangzhou Tigermed Consulting Co., Ltd Price Chart
Hangzhou Tigermed Consulting Co., Ltd 300347.SZ Financial and Trading Overview
Hangzhou Tigermed Consulting Co., Ltd stock price | 53.15 CNY |
Previous Close | 74.13 CNY |
Open | 74.15 CNY |
Bid | 73.16 CNY x 0 |
Ask | 73.17 CNY x 0 |
Day's Range | 72.33 - 74.85 CNY |
52 Week Range | 69.89 - 134.8 CNY |
Volume | 9.43M CNY |
Avg. Volume | 6.69M CNY |
Market Cap | 60.73B CNY |
Beta (5Y Monthly) | 0.831164 |
PE Ratio (TTM) | 30.86498 |
EPS (TTM) | 2.7 CNY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 31, 2022 |
1y Target Est | 132.47 CNY |
300347.SZ Valuation Measures
Enterprise Value | 60.13B CNY |
Trailing P/E | 30.86498 |
Forward P/E | 21.141619 |
PEG Ratio (5 yr expected) | 1.08 |
Price/Sales (ttm) | 8.586627 |
Price/Book (mrq) | 3.1459658 |
Enterprise Value/Revenue | 8.502 |
Enterprise Value/EBITDA | 31.639 |
Trading Information
Hangzhou Tigermed Consulting Co., Ltd Stock Price History
Beta (5Y Monthly) | 0.831164 |
52-Week Change | -23.93% |
S&P500 52-Week Change | 20.43% |
52 Week High | 134.8 CNY |
52 Week Low | 69.89 CNY |
50-Day Moving Average | 89.06 CNY |
200-Day Moving Average | 98.1 CNY |
300347.SZ Share Statistics
Avg. Volume (3 month) | 6.69M CNY |
Avg. Daily Volume (10-Days) | 8.96M CNY |
Shares Outstanding | 749.29M |
Float | 626.95M |
Short Ratio | N/A |
% Held by Insiders | 36.00% |
% Held by Institutions | 34.69% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.55 |
Trailing Annual Dividend Yield | 0.74% |
5 Year Average Dividend Yield | 36.00% |
Payout Ratio | 0.2101 |
Last Split Factor | 1.5:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 29.08% |
Operating Margin (ttm) | 24.47% |
Gross Margin | 39.84% |
EBITDA Margin | 26.87% |
Management Effectiveness
Return on Assets (ttm) | 4.08% |
Return on Equity (ttm) | 10.18% |
Income Statement
Revenue (ttm) | 7.07B CNY |
Revenue Per Share (ttm) | 8.18 CNY |
Quarterly Revenue Growth (yoy) | -0.70% |
Gross Profit (ttm) | 2.81B CNY |
EBITDA | 1.9B CNY |
Net Income Avi to Common (ttm) | 2.06B CNY |
Diluted EPS (ttm) | 2.37 |
Quarterly Earnings Growth (yoy) | 9.70% |
Balance Sheet
Total Cash (mrq) | 7.65B CNY |
Total Cash Per Share (mrq) | 8.83 CNY |
Total Debt (mrq) | 2.83B CNY |
Total Debt/Equity (mrq) | 12.14 CNY |
Current Ratio (mrq) | 2.954 |
Book Value Per Share (mrq) | 23.252 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.08B CNY |
Levered Free Cash Flow (ttm) | -398932448 CNY |
Profile of Hangzhou Tigermed Consulting Co., Ltd
Country | China |
State | N/A |
City | Hangzhou |
Address | F18, Building A – Shengda Science Park |
ZIP | 310051 |
Phone | 86 57 1288 87227 |
Website | https://www.tigermed.net |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 9233 |
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Q&A For Hangzhou Tigermed Consulting Co., Ltd Stock
What is a current 300347.SZ stock price?
Hangzhou Tigermed Consulting Co., Ltd 300347.SZ stock price today per share is 53.15 CNY.
How to purchase Hangzhou Tigermed Consulting Co., Ltd stock?
You can buy 300347.SZ shares on the Shenzhen exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hangzhou Tigermed Consulting Co., Ltd?
The stock symbol or ticker of Hangzhou Tigermed Consulting Co., Ltd is 300347.SZ.
Which industry does the Hangzhou Tigermed Consulting Co., Ltd company belong to?
The Hangzhou Tigermed Consulting Co., Ltd industry is Diagnostics & Research.
How many shares does Hangzhou Tigermed Consulting Co., Ltd have in circulation?
The max supply of Hangzhou Tigermed Consulting Co., Ltd shares is 793.25M.
What is Hangzhou Tigermed Consulting Co., Ltd Price to Earnings Ratio (PE Ratio)?
Hangzhou Tigermed Consulting Co., Ltd PE Ratio is 19.68518400 now.
What was Hangzhou Tigermed Consulting Co., Ltd earnings per share over the trailing 12 months (TTM)?
Hangzhou Tigermed Consulting Co., Ltd EPS is 2.7 CNY over the trailing 12 months.
Which sector does the Hangzhou Tigermed Consulting Co., Ltd company belong to?
The Hangzhou Tigermed Consulting Co., Ltd sector is Healthcare.